Skip to main content

Table 1 Effects of metformin and atorvastatin on laboratory parameters

From: Metformin enhances nitric oxide production and diminishes Rho kinase activity in rats with hyperlipidemia

Variables Sham Control Atorvastatin Metformin Combined
Initially      
TG (mmol/L) 0.97 ± 0.10 0.96 ± 0.12 0.95 ± 0.12 0.96 ± 0.11 0.94 ± 0.12
TC (mmol/L) 3.12 ± 0.28 3.15 ± 0.30 3.18 ± 0.32 3.16 ± 0.32 3.19 ± 0.29
LDL-C (mmol/L) 1.97 ± 0.20 1.98 ± 0.20 1.99 ± 0.22 1.96 ± 0.18 2.00 ± 0.18
HDL-C (mmol/L) 1.05 ± 0.05 1.07 ± 0.04 1.06 ± 0.04 1.06 ± 0.05 1.06 ± 0.05
CRP (mg/L) 1.34 ± 0.18 1.37 ± 0.15 1.36 ± 0.15 1.35 ± 0.17 1.37 ± 0.16
ALT (U/L) 26.2 ± 3.2 26.7 ± 3.1 27.2 ± 2.9 27.1 ± 2.4 26.8 ± 2.2
AST (U/L) 27.7 ± 2.6 27.9 ± 2.1 28.0 ± 2.5 28.3 ± 3.0 27.8 ± 2.0
CK (U/L) 13.3 ± 1.4 13.7 ± 1.2 14.2 ± 1.0 14.0 ± 1.2 13.5 ± 1.1
FBG (mmol/L) 4.64 ± 0.37 4.57 ± 0.32 4.68 ± 0.30 4.66 ± 0.33 4.74 ± 0.25
6 weeks later      
TG (mmol/L) 0.99 ± 0.10* 2.18 ± 0.31 2.17 ± 0.30 2.18 ± 0.22 2.18 ± 0.21
TC (mmol/L) 3.11 ± 0.29* 5.87 ± 0.57 5.90 ± 0.60 5.93 ± 0.62 5.91 ± 0.59
LDL-C (mmol/L) 1.95 ± 0.18* 3.83 ± 0.53 3.84 ± 0.51 3.82 ± 0.50 3.79 ± 0.50
HDL-C (mmol/L) 1.08 ± 0.05 1.09 ± 0.05 1.08 ± 0.04 1.08 ± 0.04 1.09 ± 0.05
CRP (mg/L) 1.35 ± 0.12* 7.87 ± 1.02 7.90 ± 1.06 7.88 ± 1.05 7.92 ± 1.02
ALT (U/L) 28.4 ± 3.0 29.7 ± 3.1 29.7 ± 2.2 28.8 ± 1.0 28.8 ± 1.6
AST (U/L) 28.0 ± 3.1 28.5 ± 2.2 28.1 ± 2.1 28.4 ± 2.2 28.4 ± 1.6
CK (U/L) 13.9 ± 1.2 13.2 ± 1.0 14.0 ± 1.1 13.7 ± 1.2 13.3 ± 1.5
FBG (mmol/L) 4.79 ± 0.42 5.83 ± 0.38 5.86 ± 0.35 5.92 ± 0.35 5.81 ± 0.28
4 weeks of intervention      
TG (mmol/L) 0.97 ± 0.11* 2.19 ± 0.21 1.93 ± 0.10 2.17 ± 0.18 1.93 ± 0.12
TC (mmol/L) 3.02 ± 0.22* 5.74 ± 0.36# 4.60 ± 0.38 5.79 ± 0.37 4.52 ± 0.37
LDL-C (mmol/L) 1.91 ± 0.15* 3.72 ± 0.26# 2.91 ± 0.28 3.73 ± 0.33 2.86 ± 0.16
HDL-C (mmol/L) 1.07 ± 0.04 1.08 ± 0.04 1.09 ± 0.03 1.09 ± 0.03 1.10 ± 0.04
CRP (mg/L) 1.36 ± 0.10* 7.22 ± 1.06# 5.18 ± 0.98 5.27 ± 0.78 4.53 ± 0.73&
ALT (U/L) 27.6 ± 2.1 27.9 ± 1.1 28.5 ± 2.2 28.2 ± 1.1 28.0 ± 2.1
AST (U/L) 27.9 ± 2.2 28.2 ± 2.0 28.6 ± 2.1 28.3 ± 1.8 27.9 ± 1.2
CK (U/L) 14.6 ± 1.1 13.8 ± 1.2 14.3 ± 1.2 14.2 ± 1.1 13.9 ± 1.2
FBG (mmol/L) 4.77 ± 0.46 5.71 ± 0.45 5.72 ± 0.43 4.98 ± 0.39 5.05 ± 0.45
  1. Denote: *P < 0.05 sham group versus other group, #P < 0.05 control group versus atorvastatin and combined groups, &P < 0.05 combined group versus atorvastatin and metformin groups.